Suppression of glucose transport of Ehrlich ascites tumour cell by interferon inducers

Area of Science:

• Biochemistry
• Cell Biology
• Pharmacology

Background:

• Ehrlich ascites tumor cells are a model for studying cancer cell metabolism.
• Interferon inducers are known to have immunomodulatory and potential anti-tumor effects.
• Glucose transport is a critical process for rapidly proliferating cancer cells.

Purpose of the Study:

• To investigate the effect of polyriboinosinic-polyribocytidylic acid, statolon, and tilorone on Ehrlich ascites tumor cell growth.
• To determine how these agents impact glucose uptake and glucose carrier density on tumor cells.
• To elucidate the mechanism by which interferon inducers affect glucose transport in cancer.

Main Methods:

• In vivo administration of interferon inducers to tumor-bearing mice.
• Measurement of cellular glucose uptake in tumor cells.
• Quantification of glucose carrier density on the surface of tumor cells.
• Analysis of glucose carrier kinetics (turnover and substrate affinity).

Main Results:

• Polyriboinosinic-polyribocytidylic acid, statolon, and tilorone significantly inhibited Ehrlich ascites tumor cell growth in vivo.
• These drugs markedly reduced cellular glucose uptake in tumor cells.
• A decrease in the density of glucose carriers on the tumor cell surface was observed following drug treatment.
• No qualitative alterations in the turnover rate or substrate affinity of the glucose carrier were detected.

Conclusions:

• Interferon inducers like polyriboinosinic-polyribocytidylic acid, statolon, and tilorone possess anti-proliferative effects against Ehrlich ascites tumors.
• The anti-tumor mechanism involves the inhibition of glucose transport, primarily through reduced carrier density.
• These findings highlight the role of interferon inducers in modulating cancer cell metabolism and suggest potential therapeutic strategies.